Aclaris Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Full top-line results from the ATI-052 phase I-A trial show strong PK/PD, 100% target inhibition, and excellent safety, supporting infrequent dosing. ATI-2138 advances to phase IIb in lichen planus, targeting both TCR and JAK3, with a basket study design for broad efficacy.
-
ATI-052, a bispecific antibody, shows best-in-class potency and extended dosing intervals for atopic dermatitis and asthma, with ongoing studies and no major safety concerns to date. The portfolio includes innovative small molecules and a strategy for combination regimens, with key clinical readouts expected soon.
-
The company is advancing a diversified pipeline in immunology, with key phase II data readouts for TSLP and bispecific antibodies expected by year-end. ITK inhibitors show strong preclinical and clinical promise, and a robust cash position funds operations into Q4 2028.
-
Key clinical programs are advancing, with pivotal data for bosakitug and ATI-052 expected in the second half of the year. Both programs show strong differentiation in potency, dosing, and safety, with potential expansion into multiple indications. 2026 is set as a major milestone year.
-
The discussion highlighted progress on TSLP-targeted biologics and ITK/JAK3 oral inhibitors, with key clinical readouts expected in late 2026. Next-generation ITK-selective compounds are advancing, aiming for broad efficacy and favorable safety across multiple immune-mediated indications.
-
ATI-052 showed strong safety, tolerability, and best-in-class PK/PD in a Phase 1A trial, with complete and sustained inhibition of key inflammatory pathways at low doses. The bispecific antibody outperformed comparators and supports extended dosing intervals, with Phase 1B trials in atopic dermatitis and asthma set to begin soon.
Fiscal Year 2025
-
The company is advancing a diversified pipeline of large and small molecule therapeutics, with major data readouts expected in 2026 across TSLP mAb, IL-4/TSLP bispecific, and ITK inhibitor programs. Strategic study designs and a strong cash position support efficient progress.
-
The conference highlighted a robust pipeline with four clinical-stage assets by 2026, including differentiated biologics and next-gen small molecules targeting dermatological and respiratory diseases. Key data readouts are expected in 2026, supported by strong financials.
-
A clinical-stage biotech highlighted its diversified pipeline, including a potent TSLP antibody (Bosakitug) in phase 2B for atopic dermatitis, a bispecific antibody targeting TSLP/IL-4R, and a next-gen ITK inhibitor for lichen planus. Cash runway extends into late 2028.
-
The company is advancing a diverse immunoinflammatory pipeline, including potent ITK inhibitors and TSLP-based biologics, with major clinical catalysts expected in 2026. Rigorous trial design and a strong cash position support progress across multiple indications.
-
A diversified pipeline with four clinical-stage assets is set for multiple readouts in 2026, including next-gen ITK inhibitors and bispecific antibodies targeting large immunology and dermatology markets. Strong clinical data, robust R&D, and a solid cash runway position the company for significant growth and strategic flexibility.
-
The presentation detailed a robust immuno-inflammatory pipeline, including best-in-class oral and biologic assets with strong preclinical and clinical data. Key milestones are expected in 2026, supported by a solid cash position and a multidisciplinary team.
-
Multiple clinical assets are advancing, with key data readouts expected in 2026. The bispecific and TSLP antibody programs show strong differentiation, and robust trial design aims to address high placebo rates. Financial runway extends to mid-2028, with additional non-dilutive funding options.
-
ATI-2138 demonstrated strong efficacy and a clean safety profile in phase 2a atopic dermatitis, with rapid and sustained improvements in EASI and itch scores. Pharmacodynamic data confirmed robust dual ITK/JAK3 inhibition, supporting further development in alopecia areata and other indications.
-
The conference highlighted a robust pipeline of differentiated large and small molecule assets targeting inflammation and immunology, with multiple clinical milestones expected in 2025 and 2026. Strong clinical data and financial position support ongoing development and expansion plans.
-
The company is advancing a robust immuno-inflammatory pipeline, highlighted by a best-in-class anti-TSLP antibody and a novel bispecific, with key phase II and I data readouts expected by late next year. Financial runway extends through mid-2028, supporting major clinical milestones.
-
The company is advancing a diversified pipeline with three clinical-stage assets, including a TSLP mAb in phase II for atopic dermatitis, a potent ITK/JAK3 inhibitor, and a bispecific antibody entering phase I. Strong cash reserves support key milestones through 2027, with additional value expected from partnerships and IP monetization.
-
A diversified immunoinflammatory pipeline is advancing with both small and large molecule assets, targeting atopic dermatitis and respiratory diseases. Strong cash reserves support multiple clinical catalysts through 2026, with strategic focus on efficacy and global partnerships.
-
Expanded pipeline with new antibody assets and robust cash runway supports multiple clinical programs in immunoinflammatory diseases. Key data from China and U.S. studies, including phase 2b AD and bispecific antibody trials, are expected through 2026.
Fiscal Year 2024
-
A recent in-licensing deal brought two advanced immunoinflammatory assets and a bispecific to the pipeline, validated by internal and external data. Upcoming phase 2 respiratory and atopic dermatitis readouts could drive rapid development and market differentiation.
-
A strategic review led to a Biogen license deal, $80M financing, and a strengthened pipeline with four clinical assets. BSI-045B showed robust efficacy in AD, outperforming approved biologics, and new trials in respiratory diseases are expected to read out in 2025. BSI-502 and next-gen ITK programs further expand the portfolio.
-
The company is advancing ATI-2138, a dual ITK/JAK3 inhibitor, in atopic dermatitis with data expected in early 2025, and is developing next-gen selective ITK inhibitors for broader immunoinflammatory and respiratory indications. Recent restructuring and IP monetization have extended the cash runway to 2028.
-
The session highlighted a strategic focus on immunoinflammatory disorders, with ATI-2138, a dual ITK/JAK3 inhibitor, advancing to a proof-of-concept study in atopic dermatitis. The company is leveraging a productive platform, cost controls, and partnership opportunities to drive its pipeline.